Glucose intolerance and risk of cardiovascular disease in Iranian men and women: Results of the 7.6-year follow-up of the Tehran Lipid and Glucose Study (TLGS)

Journal of Endocrinological Investigation

Volumn 32, Issue 9, 2009, Pages 724-730

  Hadaegh, F ^a   Khalili, D ^a,b   Fahimfar, N ^a,b   Tohidi, M ^a   Eskandari, F ^a   Azizi, F ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cardiovascular diseases; Cohort studies; Diabetes mellitus; Glucose intolerance; Iran

Indexed keywords

GLUCOSE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE; RISK ASSESSMENT; URBAN POPULATION;

ADULT; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GLUCOSE INTOLERANCE; HUMANS; IRAN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK; URBAN POPULATION;

EID: 74949114759     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/bf03346527     Document Type: Article

References (43)

1. Lowe LP, Liu K, Greenland P, Metzger BE, Dyer AR, Stamler J. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white Men: The Chicago Heart Association Detection Project in Industry Study. Diabetes Care 1997, 20: 163-9.
2. Saydah SH, Loria CM, Eberhardt MS, Brancati FL. Subclinical states of glucose intolerance and risk of death in the U.S. Diabetes Care 2001, 24: 447-53.
3. DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001, 161: 397-405.
4. Ma S, Cutter J, Tan CE, Chew SK, Tai ES. Associations of diabetes mellitus and ethnicity with mortality in a multiethnic Asian population: data from the 1992 Singapore National Health Survey. Am J Epidemiol 2003, 158: 543-52.
5. Barr EL, Zimmet PZ, Welborn TA, et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 2007, 116: 151-7.
6. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes- estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27: 1047-53.
7. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world - a growing challenge. N Engl J Med 2007, 356: 213-5.
8. Esteghamati A, Gouya MM, Abbasi M, et al. Prevalence of diabetes and impaired fasting glucose in the adult population of Iran: National Survey of Risk Factors for Non-Communicable Diseases of Iran. Diabetes Care 2008, 31: 96-8.
9. Hadaegh F, Bozorgmanesh MR, Ghasemi A, Harati H, Saadat N, Azizi F. High prevalence of undiagnosed diabetes and abnormal glucose tolerance in the Iranian urban population: Tehran Lipid and Glucose Study. BMC Public Health 2008, 8: 176.
10. Harris MI, Eastman RC. Early detection of undiagnosed diabetes mellitus: a US perspective. Diabetes Metab Res Rev 2000, 16: 230-6.
11. Unwin N, Shaw J, Zimmet P, Alberti KG. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 2002, 19: 708-23.
12. Estegamati A, Abbasi M, Nakhjaani M, Yousefizadeh A, Basa AP, Afshar H. Prevalence of diabetes and other cardiovascular risk factors in an Iranian population with acute coronary syndrome. Cardiovascular Diabetology 2006, 5: 15.
13. Azizi F, Rahmani M, Emami H, et al. Cardiovascular risk factors in an Iranian urban population: Tehran lipid and glucose study (phase 1). Soz Praventivmed 2002, 47: 408-26.
14. Azizi F, Ghanbarian A, Momenan AA, et al. Prevention of non-communicable disease in a population in nutrition transition: Tehran Lipid and Glucose Study Phase II (Study Protocols & Design). Trials 2009, 10: 5.
15. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18: 499-502.
16. Hadaegh F, Harati H, Ghanbarian A, Azizi F. Association of total cholesterol versus other serum lipid parameters with the short-term prediction of cardiovascular outcomes: Tehran Lipid and Glucose Study. Eur J Cardiovasc Prev Rehabil 2006, 13: 571-7.
17. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997, 20: 1183-97.
18. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome - a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006, 23: 469-80.
19. Esteghamati A, Ashraf H, Rashidi A, Meysamie A. Waist circumference cut-off points for the diagnosis of metabolic syndrome in Iranian adults. Diabetes Res Clin Pract 2008, 82: 104-7.
20. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002, 105: 310-5.
21. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285: 2486-97.
22. Coleman RL, Stevens RJ, Retnakaran R, Holman RR. Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes. Diabetes Care 2007, 30: 1292-3.
23. Stevens RJ, Coleman RL, Holman RR. Framingham risk equations underestimate coronary heart disease risk in diabetes. Diabet Med 2005, 22: 228.
24. Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003, 26: 3160-7.
25. Ken Schramm T, Gislason GH, Køber L, et al. Diabetes Patients Requiring Glucose-Lowering Therapy and Nondiabetics With a Prior Myocardial Infarction Carry the Same Cardiovascular Risk: A Population Study of 3.3 Million People. Circulation 2008, 117: 1945-54.
26. Vaccaro O, Eberly LE, Neaton JD, Yang L, Riccardi G, Stamler J. Impact of Diabetes and Previous Myocardial Infarction on Long-term Survival. 25-Year Mortality Follow-up of Primary Screenees of the Multiple Risk Factor Intervention Trial. Arch Intern Med 2004, 164: 1438-43.
27. Rodriguez BL, Lau N, Burchfiel CM, et al. Glucose intolerance and 23-year risk of coronary heart disease and total mortality: the Honolulu Heart Program. Diabetes Care 1999, 22: 1262-5.
28. Inchiostro S, Fadini GP, de Kreutzenberg SV, Citroni N, Avogaro A. Is the metabolic syndrome a cardiovascular risk factor beyond its specific components? J Am Coll Cardiol 2007, 49: 2465.
29. Kahn R. Metabolic syndrome: is it a syndrome? Does it matter? Circulation 2007, 115: 1806-11.
30. Zabetian A, Hadaegh F, Azizi F. Relationship between metabolic syndrome and its components with coronary heart disease in Iranian men and women. Exp Clin Endocrinol Diabetes 2008, 116: 525-31.
31. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006, 332: 73-8.
32. Kanaya AM, Grady D, Barrett-Connor E. Explaining the sex difference in coronary heart disease mortality among patients with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med 2002, 162: 1737-45.
33. Juutilainen A, Kortelainen S, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Gender Difference in the Impact of Type 2 Diabetes on Coronary Heart Disease Risk. Diabetes Care 2004, 27: 2898-904.
34. American Diabetes Association. Standards of medical care in diabetes-2009. Diabetes Care 2009, 1: S13-61.
35. Natarajan S, Liao Y, Sinha D, Cao G, McGee DL, Lipsitz SR. Sex differences in the effect of diabetes duration on coronary heart disease mortality. Arch Intern Med 2005, 165: 430-5.
36. Onat A, Hergenç G, Bulur S, Ugur M, Kücükdurmaz Z, Can G. The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks. Int J Cardiol 2009, [Epub ahead of print].
37. Zabetian A, Hadaegh F, Azizi F. Prevalence of metabolic syndrome in Iranian adult population, concordance between the IDF with the ATPIII and the WHO definitions. Diabetes Res Clin Pract 2007, 77: 251-7.
38. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999, 22: 233-40.
39. Blake DR, Meigs JB, Muller DC, Najjar SS, Andres R, Nathan DM. Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors: results from the Baltimore Longitudinal Study on Aging. Diabetes 2004, 53: 2095-100.
40. Pankow JS, Kwan DK, Duncan BB, et al. Cardiometabolic risk in impaired fasting glucose and impaired glucose tolerance: the Atherosclerosis Risk in Communities Study. Diabetes Care 2007, 30: 325-31.
41. Rijkelijkhuizen JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD, Dekker JM. High risk of cardiovascular mortality in individuals with impaired fasting glucose is explained by conversion to diabetes: the Hoorn study. Diabetes Care 2007, 30: 332-6.
42. Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007, 30: 753-9.
43. Levitzky YS, Pencina MJ, D'Agostino RB, et al. Impact of impaired fasting glucose on cardiovascular disease: the Framingham Heart Study. J Am Coll Cardiol 2008, 51: 264-70.